Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal
Study on B-blockers to Prevent Decompensation of Cirrhosis With HTPortal
This is a multicenter, randomized, double-blind, placebo-controlled study on the
 effectiveness of treatment with beta-blockers to prevent decompensation of cirrhosis with
 portal hypertension.
Inclusion Criteria:

 -  Between 18 and 80 years old.

 -  With liver cirrhosis diagnosed by previous biopsy or by clinical criteria, and
 analytical image.

 -  No esophageal varices (or with small varices without red signs) in a recent
 videogastroscophy (<3 months before randomization).

 -  Absence of ascites demonstrated by a recent ultrasound (<3 months before the
 randomization).

 -  informed consent

 Exclusion Criteria:

 -  previous decompensation of liver cirrhosis associated with portal hypertension.

 -  GPVH <10 mmHg.

 -  Portal axis thrombosis affecting the portal trunk or main hepatic branches, or the
 splenic or mesenteric vein.

 -  Hepatocellular carcinoma demonstrated by two imaging tests.

 -  Bilirubin> 3 mg / dl (or> 50 micromol / l), platelets <30 x10E9/lo Quick <30%.

 -  Presence of renal insufficiency (serum creatinine> 2 mg / dl or> 200 micromol / l).

 -  Any comorbidity involving a therapeutic limitation and / or a prognosis of life <12
 months.

 -  Absolute contraindication to treatment with β-blockers (severe bronchospasm, stenosis
 aortic A-V block, intermittent claudication, severe psychosis, bronchial asthma)

 -  Hypersensitivity to β-blockers.

 -  Pregnancy or lactation.

 -  To receive anticoagulant treatment.

 -  Past treatment with nitrated or β-blockers in the two weeks prior inclusion.

 -  Cirrhosis C virus active antiviral therapy.